Physician profile
Sandra Reed
NPI 1194319806
$9,663.44
in general payments reported to CMS, 2019-2025
47 companies · $3,425 in 2025
The $3,425 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $1,206 · 2023: $2,689 · 2024: $1,598 · 2025: $3,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,678 · Education: $34.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,677.86 |
| Education | $34.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,427.11 | 2022-2025 | Krystexxa, Otezla, Otezla |
| Abbvie INC. | $1,133.80 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,073.19 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $885.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $825.84 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $491.97 | 2022-2025 | Rexulti, Abilify Maintena |
| Ani Pharmaceuticals, INC. | $429.49 | 2023-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $331.66 | 2022-2025 | |
| Novo Nordisk INC | $297.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $225.59 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $207.54 | 2021 | |
| Lilly USA, LLC | $196.71 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Mannkind Corporation | $195.29 | 2023-2025 | V-Go, Afrezza |
| Neurocrine Biosciences, INC. | $160.32 | 2023-2025 | Ingrezza |
| Abbott Laboratories | $139.60 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.